215 related articles for article (PubMed ID: 33082400)
1. MLH1 single-nucleotide variant in circulating tumor DNA predicts overall survival of patients with hepatocellular carcinoma.
Kim SS; Eun JW; Choi JH; Woo HG; Cho HJ; Ahn HR; Suh CW; Baek GO; Cho SW; Cheong JY
Sci Rep; 2020 Oct; 10(1):17862. PubMed ID: 33082400
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma.
Cai ZX; Chen G; Zeng YY; Dong XQ; Lin MJ; Huang XH; Zhang D; Liu XL; Liu JF
Int J Cancer; 2017 Sep; 141(5):977-985. PubMed ID: 28543104
[TBL] [Abstract][Full Text] [Related]
3. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
[TBL] [Abstract][Full Text] [Related]
4. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma.
Cai Z; Chen G; Zeng Y; Dong X; Li Z; Huang Y; Xin F; Qiu L; Xu H; Zhang W; Su X; Liu X; Liu J
Clin Cancer Res; 2019 Sep; 25(17):5284-5294. PubMed ID: 31217202
[TBL] [Abstract][Full Text] [Related]
6. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.
von Felden J; Craig AJ; Garcia-Lezana T; Labgaa I; Haber PK; D'Avola D; Asgharpour A; Dieterich D; Bonaccorso A; Torres-Martin M; Sia D; Sung MW; Tabrizian P; Schwartz M; Llovet JM; Villanueva A
Oncogene; 2021 Jan; 40(1):140-151. PubMed ID: 33097857
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
Hirai M; Kinugasa H; Nouso K; Yamamoto S; Terasawa H; Onishi Y; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Onishi H; Shiraha H; Takaki A; Okada H
J Gastroenterol Hepatol; 2021 Apr; 36(4):1118-1125. PubMed ID: 32830343
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
Ikeda S; Lim JS; Kurzrock R
Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
[TBL] [Abstract][Full Text] [Related]
10. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma.
Jiang P; Sun K; Tong YK; Cheng SH; Cheng THT; Heung MMS; Wong J; Wong VWS; Chan HLY; Chan KCA; Lo YMD; Chiu RWK
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10925-E10933. PubMed ID: 30373822
[TBL] [Abstract][Full Text] [Related]
11. Applications of next-generation sequencing analysis for the detection of hepatocellular carcinoma-associated hepatitis B virus mutations.
Wu IC; Liu WC; Chang TT
J Biomed Sci; 2018 Jun; 25(1):51. PubMed ID: 29859540
[TBL] [Abstract][Full Text] [Related]
12. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.
Alunni-Fabbroni M; Rönsch K; Huber T; Cyran CC; Seidensticker M; Mayerle J; Pech M; Basu B; Verslype C; Benckert J; Malfertheiner P; Ricke J
J Transl Med; 2019 Oct; 17(1):328. PubMed ID: 31570105
[TBL] [Abstract][Full Text] [Related]
13. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study.
Pommergaard HC; Yde CW; Ahlborn LB; Andersen CL; Henriksen TV; Hasselby JP; Rostved AA; Sørensen CL; Rohrberg KS; Nielsen FC; Rasmussen A
Mol Biol Rep; 2022 Feb; 49(2):1609-1616. PubMed ID: 34811635
[TBL] [Abstract][Full Text] [Related]
14. Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with
Lim HY; Merle P; Weiss KH; Yau T; Ross P; Mazzaferro V; Blanc JF; Ma YT; Yen CJ; Kocsis J; Choo SP; Sukeepaisarnjaroen W; Gérolami R; Dufour JF; Gane EJ; Ryoo BY; Peck-Radosavljevic M; Dao T; Yeo W; Lamlertthon W; Thongsawat S; Teufel M; Roth K; Reis D; Childs BH; Krissel H; Llovet JM
Clin Cancer Res; 2018 Oct; 24(19):4650-4661. PubMed ID: 29950351
[No Abstract] [Full Text] [Related]
15. Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study.
Zhu GQ; Liu WR; Tang Z; Qu WF; Fang Y; Jiang XF; Song SS; Wang H; Tao CY; Zhou PY; Huang R; Gao J; Sun HX; Ding ZB; Peng YF; Dai Z; Zhou J; Fan J; Shi YH
Mol Oncol; 2022 Jan; 16(2):549-561. PubMed ID: 34543520
[TBL] [Abstract][Full Text] [Related]
16. The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma.
Ding Y; Yao J; Wen M; Liu X; Huang J; Zhang M; Zhang Y; Lv Y; Xie Z; Zuo J
PeerJ; 2022; 10():e13473. PubMed ID: 35602894
[TBL] [Abstract][Full Text] [Related]
17. Individualized Mutation Detection in Circulating Tumor DNA for Monitoring Colorectal Tumor Burden Using a Cancer-Associated Gene Sequencing Panel.
Sato KA; Hachiya T; Iwaya T; Kume K; Matsuo T; Kawasaki K; Abiko Y; Akasaka R; Matsumoto T; Otsuka K; Nishizuka SS
PLoS One; 2016; 11(1):e0146275. PubMed ID: 26727500
[TBL] [Abstract][Full Text] [Related]
18. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas.
Dhayat SA; Yang Z
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1625-1645. PubMed ID: 32338295
[TBL] [Abstract][Full Text] [Related]
19. Current status of ctDNA in precision oncology for hepatocellular carcinoma.
Li Y; Zheng Y; Wu L; Li J; Ji J; Yu Q; Dai W; Feng J; Wu J; Guo C
J Exp Clin Cancer Res; 2021 Apr; 40(1):140. PubMed ID: 33902698
[TBL] [Abstract][Full Text] [Related]
20. Exploration of CTNNB1 ctDNA as a putative biomarker for hepatoblastoma.
Kahana-Edwin S; McCowage G; Cain L; Saletta F; Yuksel A; Graf N; Karpelowsky J
Pediatr Blood Cancer; 2020 Nov; 67(11):e28594. PubMed ID: 32881242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]